Danaher Corporation

Equities

DHR

US2358511028

Market Closed - Nyse Other stock markets 04:00:02 2025-06-23 pm EDT			5-day change	1st Jan Change
196.34 ^USD	-0.03%		-2.37%	-14.47%

07:53am	Barclays Adjusts Danaher Price Target to $225 From $215	MT
Jun. 09	Some of the biggest splits in Corporate America	RE

Danaher Corporation Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 10:00 AM

Published on 05/15/2025 at 14:20, updated on 05/15/2025 at 15:06

Presenter Speech
Michael Ryskin (Analysts)

And I'm excited to host our next session. We're joined by Danaher. I'm joined by Rainer Blair, CEO. Rainer, thanks so much for being here.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Danaher Corporation

Barclays Adjusts Danaher Price Target to $225 From $215	07:53am	MT
Some of the biggest splits in Corporate America	Jun. 09	RE
Some of the biggest splits in Corporate America	Jun. 09	RE
Deutsche Bank Adjusts Danaher Price Target to $235 From $240	Jun. 05	MT
Sciex And Evosep Expand Access To Standardized Proteomics For Pharma And Biotech With New Reseller Agreement	Jun. 02	RE
Software Launches For Sciex Os Ecosystem	Jun. 02	RE
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	May. 30	MT
Danaher partners with AstraZeneca to develop AI diagnostics	May. 30	AN
Danaher Announces Diagnostic Development And Commercialization Partnership To Scale Precision Medicine	May. 29	RE
Danaher, AstraZeneca Collaborate on Precision Medicine	May. 29	MT
Danaher Corporation Announces the Launch of Partnership with AstraZeneca to Develop and Commercialize Novel Diagnostic Tools and Tests Intended to Help Clinicians Better Determine Which Patients Would Most Benefit from Precision Medicine Treatments	May. 29	CI
Danaher, AstraZeneca Form Partnership For Diagnostic Development	May. 29	DJ
Third Point LLC Dissolves Share Stake In Meta, Thermo Fisher Scientific & Cuts Share Stake In Microsoft	May. 15	RE
Danaher Corporation Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 10:00 AM	May. 15
Danaher Insider Sold Shares Worth $245,919,391, According to a Recent SEC Filing	May. 14	MT
Third Point Investors says fund down in first quarter amid tariffs	May. 02	AN
Danaher Insider Sold Shares Worth $3,129,424, According to a Recent SEC Filing	May. 01	MT
Veralto posts upbeat first-quarter results, shares up	Apr. 29	RE
Danaher Unit Signs Joint Marketing Deal With Kytopen for Cell Therapy Manufacturing Product	Apr. 29	MT
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook	Apr. 28	RE
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook	Apr. 28	RE
HSBC Adjusts Danaher Price Target to $240 From $270	Apr. 25	MT
Argus Cuts Price Target on Danaher to $240 From $260	Apr. 23	MT
UBS Adjusts Danaher Price Target to $240 From $275, Maintains Buy Rating	Apr. 23	MT
TD Cowen Adjusts Price Target on Danaher to $248 From $240, Maintains Buy Rating	Apr. 23	MT